AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has provided an announcement.
AIM Vaccine Co., Ltd. has announced proposed amendments to its Articles of Association in response to changes in The Company Law of the People’s Republic of China, effective from July 1, 2024. These amendments include altering the number of directors on the board and removing the supervisory committee, pending shareholder approval at the annual general meeting on May 20, 2025. This move is expected to streamline the company’s governance structure, potentially impacting its operational efficiency and aligning with regulatory requirements.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on the development and production of vaccines, contributing to public health initiatives by providing essential immunization solutions.
YTD Price Performance: -44.79%
Average Trading Volume: 6,162,144
Technical Sentiment Signal: Buy
See more data about 6660 stock on TipRanks’ Stock Analysis page.